HRP20120560T1 - Postupci, farmaceutski pripravci i proizvodi namijenjeni primjeni terapijskih stanica u središnji živčani sustav životinje - Google Patents
Postupci, farmaceutski pripravci i proizvodi namijenjeni primjeni terapijskih stanica u središnji živčani sustav životinje Download PDFInfo
- Publication number
- HRP20120560T1 HRP20120560T1 HRP20120560AT HRP20120560T HRP20120560T1 HR P20120560 T1 HRP20120560 T1 HR P20120560T1 HR P20120560A T HRP20120560A T HR P20120560AT HR P20120560 T HRP20120560 T HR P20120560T HR P20120560 T1 HRP20120560 T1 HR P20120560T1
- Authority
- HR
- Croatia
- Prior art keywords
- therapeutic cells
- cells
- accordance
- therapeutic
- intended
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract 33
- 210000003169 central nervous system Anatomy 0.000 title claims abstract 15
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 3
- 241001465754 Metazoa Species 0.000 title claims 9
- 238000000034 method Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims abstract 9
- 210000003928 nasal cavity Anatomy 0.000 claims abstract 8
- 230000003115 biocidal effect Effects 0.000 claims abstract 4
- 230000008499 blood brain barrier function Effects 0.000 claims abstract 4
- 210000001218 blood-brain barrier Anatomy 0.000 claims abstract 4
- 230000006378 damage Effects 0.000 claims abstract 4
- 230000007850 degeneration Effects 0.000 claims abstract 3
- 229940125721 immunosuppressive agent Drugs 0.000 claims abstract 3
- 239000003018 immunosuppressive agent Substances 0.000 claims abstract 3
- 230000001105 regulatory effect Effects 0.000 claims abstract 3
- 210000004027 cell Anatomy 0.000 claims 31
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 208000025966 Neurological disease Diseases 0.000 claims 3
- 108010003272 Hyaluronate lyase Proteins 0.000 claims 2
- 102000001974 Hyaluronidases Human genes 0.000 claims 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims 2
- 102000014413 Neuregulin Human genes 0.000 claims 2
- 108050003475 Neuregulin Proteins 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims 2
- 229960002773 hyaluronidase Drugs 0.000 claims 2
- 230000005012 migration Effects 0.000 claims 2
- 238000013508 migration Methods 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000000196 olfactory nerve Anatomy 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
Abstract
Terapijske stanice, koje nisu ljudske embrionske matične stanice, namijenjene upotrebi u liječenju oštećenog ili degeneriranog ili ozlijeđenog središnjog živčanog sustava životinje, gdje je oštećenje ili degeneracija rezultat neurološke bolesti ili stanja koje uzrokuje gubitak ili smrt stanica središnjeg živčanog sustava, naznačene time što se navedeno liječenje sastoji u: primjeni terapijskih stanica u gornju trećinu nosne šupljine životinje; i omogućavanju da terapijske stanice dospiju u oštećeni središnji živčani sustav zaobilaženjem krvno-moždane barijere. Patent sadrži još 14 patentnih zahtjeva.
Claims (15)
1. Terapijske stanice, koje nisu ljudske embrionske matične stanice, namijenjene upotrebi u liječenju oštećenog ili degeneriranog ili ozlijeđenog središnjog živčanog sustava životinje, gdje je oštećenje ili degeneracija rezultat neurološke bolesti ili stanja koje uzrokuje gubitak ili smrt stanica središnjeg živčanog sustava, naznačene time što se navedeno liječenje sastoji u:
primjeni terapijskih stanica u gornju trećinu nosne šupljine životinje; i omogućavanju da terapijske stanice dospiju u oštećeni središnji živčani sustav zaobilaženjem krvno-moždane barijere.
2. Terapijske stanice namijenjene upotrebi u skladu s patentnim zahtjevom 1, naznačene time što se navedeno liječenje dodatno sastoji u primjeni terapijskih stanica u tkivo inervirano njušnim živcem, gdje najmanje jedna terapijska stanica zaobilazi krvno-moždanu barijeru kako bi dospijela u oštećeni središnji živčani sustav; i minimaliziranju sistemskog unosa terapijskih stanica izvan središnjog živčanog sustava.
3. Terapijske stanice namijenjene upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačene time što se navedeno liječenje dodatno sastoji u primjeni u gornju trećinu nosne šupljine životinje najmanje jednog sredstva za poboljšavanje unosa u djelotvornoj količini u farmaceutski pripravak koji sadrži terapijske stanice, ili prije primjene terapijskih stanica.
4. Terapijske stanice namijenjene upotrebi u skladu s patentnim zahtjevom 3, naznačene time što najmanje jedno sredstvo za poboljšavanje unosa uključuje jedno iz skupine koju čine hijaluronidaza, lipofilna sredstva, čimbenik inhibicije leukemije, aktivator migracije i neuregulin.
5. Terapijske stanice namijenjene upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačene time što terapijske stanice uključuju najmanje jedno iz skupine koju čine eukariotske stanice i matične stanice.
6. Terapijske stanice namijenjene upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačene time što se navedeno liječenje dodatno sastoji u primjeni najmanje jedne terapijske stanice u gornju trećinu nosne šupljine životinje u fiziološki djelotvornoj količini kako bi se osiguralo terapijsko djelovanje, koje se sastoji u zamjeni izgubljenih i/ili umirućih stanica u oštećenom središnjom živčanom sustavu.
7. Terapijske stanice namijenjene upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačene time što neurološka bolest ili stanje uključuje najmanje jedno iz skupine koju čine Parkinsonova bolest, Alzheimerova bolest i ishemija.
8. Terapijske stanice namijenjene upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačene time što se navedeno liječenje dodatno sastoji u predobradi gornje trećine nosne šupljine najmanje jednim antibiotikom u djelotvornoj količini prije primjene terapijskih stanica.
9. Terapijske stanice namijenjene upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačene time što se navedeno liječenje dodatno sastoji u dodavanju, u djelotvornoj količini, najmanje jednog iz skupine koju čine antibiotik, regulacijsko sredstvo i imunosupresivno sredstvo, u farmaceutski pripravak koji sadrži terapijske stanice, ili prije primjene terapijskih stanica.
10. Terapijske stanice namijenjene upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačene time što se navedeno liječenje dodatno sastoji u primjeni farmaceutskog pripravka koji sadrži terapijske stanice u gornju trećinu nosne šupljine životinje u fiziološki djelotvornoj količini kako bi se osiguralo terapijsko djelovanje, koje se sastoji u zamjeni izgubljenih i/ili umirućih stanica u oštećenom središnjom živčanom sustavu.
11. Farmaceutski pripravak namijenjen upotrebi u liječenju oštećenog ili degeneriranog ili ozlijeđenog središnjog živčanog sustava životinje, gdje je oštećenje ili degeneracija rezultat neurološke bolesti ili stanja koje uzrokuje gubitak ili smrt stanica središnjeg živčanog sustava, naznačen time što sadrži:
terapijske stanice, koje nisu ljudske embrionske matične stanice, gdje se liječenje sastoji u primjeni farmaceutskog pripravka u gornju trećinu nosne šupljine životinje; uz omogućavanje da terapijske stanice dospiju u oštećeni središnji živčani sustav zaobilaženjem krvno-moždane barijere.
12. Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što sadrži terapijske stanice u skladu s bilo kojim od patentnih zahtjeva 1-10.
13. Farmaceutski pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 11 ili 12, naznačen time što dodatno sadrži najmanje jedno iz skupine koju čine sredstvo za poboljšavanje unosa, antibiotik, imunosupresivno sredstvo i regulacijsko sredstvo.
14. Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 13, naznačen time što je sredstvo za poboljšavanje unosa najmanje jedno iz skupine koju čine hijaluronidaza, lipofilna sredstva, čimbenik inhibicije leukemije, aktivator migracije i neuregulin.
15. Terapijske stanice ili farmaceutski pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je životinja sisavac.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97128407P | 2007-09-11 | 2007-09-11 | |
| US12/109,066 US8283160B2 (en) | 2007-09-11 | 2008-04-24 | Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system |
| PCT/US2008/075223 WO2009035901A1 (en) | 2007-09-11 | 2008-09-04 | Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120560T1 true HRP20120560T1 (hr) | 2012-08-31 |
Family
ID=40432083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120560AT HRP20120560T1 (hr) | 2007-09-11 | 2012-07-06 | Postupci, farmaceutski pripravci i proizvodi namijenjeni primjeni terapijskih stanica u središnji živčani sustav životinje |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US8283160B2 (hr) |
| EP (1) | EP2200621B1 (hr) |
| JP (2) | JP5600294B2 (hr) |
| KR (2) | KR20150039197A (hr) |
| CN (2) | CN101801397A (hr) |
| AT (1) | ATE554778T1 (hr) |
| AU (1) | AU2008299124B2 (hr) |
| BR (1) | BRPI0816325B8 (hr) |
| CA (1) | CA2696892C (hr) |
| CR (1) | CR11304A (hr) |
| CY (1) | CY1113120T1 (hr) |
| DK (1) | DK2200621T3 (hr) |
| ES (1) | ES2388403T3 (hr) |
| HR (1) | HRP20120560T1 (hr) |
| IL (1) | IL204371A (hr) |
| MX (1) | MX2010002738A (hr) |
| MY (1) | MY154061A (hr) |
| PL (1) | PL2200621T3 (hr) |
| PT (1) | PT2200621E (hr) |
| RU (1) | RU2468818C2 (hr) |
| SG (1) | SG184724A1 (hr) |
| SI (1) | SI2200621T1 (hr) |
| UA (1) | UA98507C2 (hr) |
| WO (1) | WO2009035901A1 (hr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8518390B2 (en) * | 2003-06-27 | 2013-08-27 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells |
| US8283160B2 (en) | 2007-09-11 | 2012-10-09 | Frey Ii William H | Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system |
| EP2153844A1 (en) * | 2008-08-14 | 2010-02-17 | HAUBECK, Hans-Dieter | Human hyaluronidases for axonal regrowth |
| MX339624B (es) | 2008-08-20 | 2016-06-02 | Anthrogenesis Corp | Composiciones mejoradas de celulas y metodos para preparar las mismas. |
| US8609088B2 (en) | 2011-05-10 | 2013-12-17 | Regents Of The University Of Minnesota | Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases |
| US8387798B1 (en) | 2012-04-27 | 2013-03-05 | Abdulmohsen E. A. H. Al-Terki | Mutiple oral and nasal surgical procedures method and kit |
| US10022083B2 (en) | 2011-06-02 | 2018-07-17 | Abdulmohsen E. A. H. Al-Terki | Multiple oral and nasal surgical procedures method and kit |
| US9821149B2 (en) * | 2011-10-14 | 2017-11-21 | Healthpartners Research & Education | Methods for using ultrasound for enhancing efficiency and targeting of intranasal administration of therapeutic compounds to the central nervous system |
| JP6301263B2 (ja) | 2011-12-23 | 2018-03-28 | デピュイ・シンセス・プロダクツ・インコーポレイテッド | ヒト臍帯組織由来細胞の検出 |
| US20130336928A1 (en) * | 2012-06-18 | 2013-12-19 | Healthpartners Research & Education | Methods and pharmaceutical compositions for treatment of central nervous system disorders with therapeutic agent(s) in patients with concurrent non-cns condition(s) or disorders contraindicating systemic administration of the therapeutic agent(s) |
| FR3001974B1 (fr) | 2013-02-08 | 2016-02-12 | Olivier Schussler | Procede de purification de cellules |
| RU2522816C1 (ru) * | 2013-02-12 | 2014-07-20 | Российская Федерация, от имени которой выступает Министерство промышленности и торговли Российской Федерации (Минпромторг России) | Композиция для клеточно-заместительной терапии дефектов мягких тканей |
| US10279012B2 (en) * | 2013-03-11 | 2019-05-07 | Healthpartners Research & Education | Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin |
| CN105377039A (zh) | 2013-05-15 | 2016-03-02 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
| US9993472B2 (en) | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
| WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
| WO2015134869A2 (en) * | 2014-03-06 | 2015-09-11 | Children's National Medical Center | Treatment of neonatal brain injury with hb-egf |
| US11413408B2 (en) | 2014-07-29 | 2022-08-16 | Peter Edenhoffer | Positive pressure inspiration device for delivery of medicaments |
| CA2956447C (en) * | 2014-07-29 | 2023-04-11 | Peter EDENHOFFER | Positive pressure inspiration device for delivery of medicaments |
| US10130657B2 (en) | 2015-02-13 | 2018-11-20 | John C. Hughes | Formulation, apparatus, and methods for treatment of brain trauma |
| US10335435B2 (en) | 2015-05-22 | 2019-07-02 | Marco Merida | Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach |
| US20160361253A1 (en) * | 2015-06-13 | 2016-12-15 | Noveome Biotherapeutics, Inc. | Novel Methods for Delivering Therapeutic Agents to the Eye via Nasal Passages |
| US11559483B2 (en) * | 2015-07-10 | 2023-01-24 | Sanjay Gupta | Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene |
| KR20180100107A (ko) * | 2015-08-13 | 2018-09-07 | 다이액스 코포레이션 | 접촉 시스템 활성화의 평가를 위한 프로테아제 저해제를 함유하는 진공 채혈관 |
| EP3452104A1 (en) | 2016-04-15 | 2019-03-13 | The Trustees of The University of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
| CN106924286A (zh) * | 2017-02-16 | 2017-07-07 | 上海安集协康生物技术股份有限公司 | 一种经鼻腔给药用于帕金森病治疗的神经干细胞制剂 |
| CN108732355B (zh) * | 2017-04-25 | 2021-06-25 | 首都医科大学附属北京安定医院 | 一种测定bace1酶切nrg1活性的检测方法及其试剂盒 |
| US20190060109A1 (en) * | 2017-08-31 | 2019-02-28 | Gregory Todd Johnson | Method of Preventing Traumatic Brain Injury (TBI) |
| EP3684938A1 (en) | 2017-09-22 | 2020-07-29 | The Trustees of the University of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
| CN108096280A (zh) * | 2017-12-28 | 2018-06-01 | 上海安集协康生物技术股份有限公司 | 一种神经干细胞滴鼻剂 |
| KR20220005900A (ko) * | 2020-07-07 | 2022-01-14 | 가톨릭대학교 산학협력단 | 뇌신경계질환 예방 또는 치료용 약학적 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5624898A (en) * | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
| US20040266715A1 (en) * | 1999-03-31 | 2004-12-30 | Wong Liang Fong | Neurite regeneration |
| US6667176B1 (en) * | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| EP1137401B1 (en) * | 1998-12-09 | 2005-11-23 | Chiron Corporation | Administration of neurotrophic agents to the central nervous system |
| ATE407695T1 (de) * | 1999-02-09 | 2008-09-15 | Riken | Tumorimpfstoff |
| US6749850B1 (en) * | 1999-08-18 | 2004-06-15 | The General Hospital Corporation | Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| US20020169102A1 (en) * | 2001-04-03 | 2002-11-14 | Frey William H. | Intranasal delivery of agents for regulating development of implanted cells in the CNS |
| JP3886346B2 (ja) * | 2001-06-22 | 2007-02-28 | サンバイオ，インコーポレイティド | 骨髄間質細胞由来Ｓｃｈｗａｎｎ細胞を含む神経再生用医薬組成物 |
| EP1438942A1 (en) * | 2003-01-17 | 2004-07-21 | Schering Oy | An otorhinological drug delivery device |
| ES2579804T3 (es) * | 2003-12-02 | 2016-08-16 | Celavie Biosciences, Llc | Composiciones y métodos para la propagación de células progenitoras neurales |
| WO2007002664A2 (en) * | 2005-06-22 | 2007-01-04 | Massachusetts Institute Of Technology | Propagation of undifferentiated embryonic stem cells in hyaluronic acid hydrogel |
| US9456979B2 (en) * | 2006-04-27 | 2016-10-04 | Sri International | Adminstration of intact mammalian cells to the brain by the intranasal route |
| US8168169B2 (en) * | 2006-08-09 | 2012-05-01 | Mclean Hospital Corporation | Methods and compositions for the treatment of medical disorders |
| US8283160B2 (en) | 2007-09-11 | 2012-10-09 | Frey Ii William H | Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system |
-
2008
- 2008-04-24 US US12/109,066 patent/US8283160B2/en active Active
- 2008-09-04 AT AT08831016T patent/ATE554778T1/de active
- 2008-09-04 ES ES08831016T patent/ES2388403T3/es active Active
- 2008-09-04 PT PT08831016T patent/PT2200621E/pt unknown
- 2008-09-04 SG SG2012066049A patent/SG184724A1/en unknown
- 2008-09-04 WO PCT/US2008/075223 patent/WO2009035901A1/en active Application Filing
- 2008-09-04 MY MYPI2010001011A patent/MY154061A/en unknown
- 2008-09-04 DK DK08831016.4T patent/DK2200621T3/da active
- 2008-09-04 CN CN200880107049A patent/CN101801397A/zh active Pending
- 2008-09-04 CN CN2012105792811A patent/CN103181932A/zh active Pending
- 2008-09-04 UA UAA201002678A patent/UA98507C2/ru unknown
- 2008-09-04 CA CA2696892A patent/CA2696892C/en active Active
- 2008-09-04 JP JP2010524134A patent/JP5600294B2/ja active Active
- 2008-09-04 AU AU2008299124A patent/AU2008299124B2/en active Active
- 2008-09-04 BR BRPI0816325A patent/BRPI0816325B8/pt active IP Right Grant
- 2008-09-04 KR KR1020157002065A patent/KR20150039197A/ko not_active Application Discontinuation
- 2008-09-04 KR KR1020107007866A patent/KR101504110B1/ko active IP Right Grant
- 2008-09-04 SI SI200830702T patent/SI2200621T1/sl unknown
- 2008-09-04 EP EP08831016A patent/EP2200621B1/en active Active
- 2008-09-04 MX MX2010002738A patent/MX2010002738A/es active IP Right Grant
- 2008-09-04 RU RU2010113932/15A patent/RU2468818C2/ru active
- 2008-09-04 PL PL08831016T patent/PL2200621T3/pl unknown
-
2010
- 2010-03-09 CR CR11304A patent/CR11304A/es unknown
- 2010-03-09 IL IL204371A patent/IL204371A/en active IP Right Grant
-
2012
- 2012-07-06 HR HRP20120560AT patent/HRP20120560T1/hr unknown
- 2012-07-20 CY CY20121100643T patent/CY1113120T1/el unknown
- 2012-10-08 US US13/647,066 patent/US20130028874A1/en not_active Abandoned
-
2014
- 2014-03-03 JP JP2014040359A patent/JP2014098051A/ja not_active Withdrawn
-
2016
- 2016-03-28 US US15/082,210 patent/US9445991B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120560T1 (hr) | Postupci, farmaceutski pripravci i proizvodi namijenjeni primjeni terapijskih stanica u središnji živčani sustav životinje | |
| Windebank et al. | The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro | |
| BRPI0509400A (pt) | métodos para tratar ou prevenir sono disfuncional, para controlar sono disfuncional e para melhorar o tempo para o começo do sono, a duração do sono ou a qualidade do sono ou realçar a capacidade para levantar sentindo-se renovado depois de um sono noturno, composição farmacêutica, e, kit adequado para o uso no tratamento, prevenção ou controle de sono disfuncional | |
| JP2016516023A5 (hr) | ||
| ZA200801732B (en) | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | |
| WO2015135089A1 (es) | Método terapéutico fármaco-celular para el tratamiento de distrofias musculares | |
| WO2010005580A3 (en) | Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity | |
| BRPI0607536A2 (pt) | tratamento de dor | |
| JP2018500390A5 (hr) | ||
| MX2011011459A (es) | Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos. | |
| EP2510941A3 (en) | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist | |
| AR079683A1 (es) | Formulacion topica oftalmica de peptidos | |
| Ferraro et al. | Neurotensin receptors as modulators of glutamatergic transmission | |
| Gattazzo et al. | Cyclosporin A promotes in vivo myogenic response in collagen VI-deficient myopathic mice | |
| Chaperon et al. | Effects of dopaminergic D3-receptor-preferring ligands on the acquisition of place conditioning in rats | |
| de Queiroz et al. | Calcitonin-gene related peptide is a potent inducer of oedema in rat orofacial tissue | |
| Mirzaei et al. | Anticholinergic, antimicrobial, and anticancer perspectives of atropine: a mini-review | |
| Cardinaal et al. | Histological effects of co-administration of an ACTH (4–9) analogue, ORG 2766, on cisplatin ototoxicity in the albino guinea pig | |
| Di Giulio et al. | Glycosaminoglycans co-administration enhance insulin-like growth factor-I neuroprotective and neuroregenerative activity in traumatic and genetic models of motor neuron disease: a review | |
| WO2016205459A3 (en) | Therapeutic nanofiber hydrogels for local treatment of brain-related diseases | |
| Marques et al. | Myocardial fibrosis is unaltered by long-term administration of L-arginine in dystrophin deficient mdx mice: a histomorphometric analysis | |
| MX2007014803A (es) | Composiciones que penetran el nucleo celular. | |
| JP2015502368A5 (hr) | ||
| WO2022150167A3 (en) | Novel macrocyclic opioid peptides | |
| JPWO2016035804A1 (ja) | 掻痒性皮膚疾患の治療又は予防剤 |